Physician profile
Jason E Seavolt
NPI 1013947456
$1,797.52
in general payments reported to CMS, 2019-2025
23 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $17.46 · 2021: $12.06 · 2022: $318 · 2023: $475 · 2024: $574 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $435.96 | 2022-2024 | Pylarify |
| Bayer Healthcare Pharmaceuticals INC. | $299.97 | 2022-2025 | |
| Pfizer INC. | $238.29 | 2022-2025 | |
| Astellas Pharma US INC | $110.95 | 2023-2024 | Xtandi |
| Sumitomo Pharma America, INC. | $95.20 | 2023-2024 | Orgovyx |
| Boston Scientific Corporation | $69.17 | 2022-2023 | Spaceoar Vue System - 10ml, Spaceoar System |
| Dendreon Pharmaceuticals LLC | $56.47 | 2023 | Provenge |
| Amgen INC. | $53.97 | 2019-2022 | |
| Accord Healthcare, INC. | $51.25 | 2024 | |
| Agios Pharmaceuticals, INC. | $50.34 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $47.58 | 2025 | Prolaris |
| Novartis Pharmaceuticals Corporation | $46.85 | 2023-2025 | |
| Myovant Sciences INC. | $37.40 | 2022 | |
| Palette Life Sciences, INC. | $34.63 | 2022-2023 | |
| Telix Pharmaceuticals | $30.65 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.55 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.37 | 2019 | |
| Celgene Corporation | $19.34 | 2019 | |
| Urogen Pharma, INC. | $18.36 | 2022 | |
| Tesaro, INC. | $17.27 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.08 | 2019 | |
| Genzyme Corporation | $12.06 | 2021 | |
| Seagen INC. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Seavolt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.